论文部分内容阅读
目的:探讨乳腺癌免疫表型分化规律及临床意义。方法:采用免疫组化SP法检测CK5、CK8及P63在136例乳腺浸润性导管癌中的表达,分析乳腺癌免疫表型分化规律及其与临床病理特征的关系。结果:CK5在乳腺浸润性导管癌中表达较弱,CK8在乳腺浸润性导管癌表达较强;109例(80.15%)乳腺浸润性导管癌呈现CK5-/CK8+腺腔表型,9例(6.62%)呈现CK5+/CK8-干细胞表型,15例(11.03%)呈现CK5+/CK8+混合表型,3例(2.21%)呈现CK5-/CK8-表型,且这种表达与患者的年龄、肿瘤分化程度、淋巴结转移以及临床分期相关;P63在乳腺浸润性导管癌中有11例(8.81%)呈现少量的肿瘤细胞阳性,并且主要表达于低分化的乳腺癌中。结论:CK5+/CK8+、CK5+/CK8-或P63+表型乳腺癌恶性程度高、预后差,免疫表型可作为评价预后的生物学指标。
Objective: To investigate the immunophenotypic differentiation and clinical significance of breast cancer. Methods: The expressions of CK5, CK8 and P63 in 136 cases of invasive ductal carcinoma of the breast were detected by immunohistochemical SP method. The relationship between the immunophenotypic differentiation and clinicopathological features of breast cancer was analyzed. Results: The expression of CK5 was weak in infiltrating ductal carcinoma of breast and CK8 in ductal infiltrating ductal carcinoma. CK5- / CK8 + glandular cavity phenotype in 109 cases (80.15%) of breast infiltrating ductal carcinomas, 9 cases (6.62 %) Showed CK5 + / CK8- stem cell phenotype, 15 (11.03%) showed CK5 + / CK8 + mixed phenotype, and 3 (2.21%) presented CK5- / CK8- phenotype, and the expression was correlated with age, Lymph node metastasis and clinical stage. P63 in breast invasive ductal carcinoma in 11 cases (8.81%) showed a small number of tumor cells were positive, and mainly expressed in poorly differentiated breast cancer. Conclusion: CK5 + / CK8 +, CK5 + / CK8- or P63 + breast cancer has a high degree of malignancy and poor prognosis. Immunophenotype can be used as a biological indicator to evaluate the prognosis.